Taken together, these results suggest that angiotensin II mediates oxidative stress and the consequent TGF 1 expression and alveolar epithelial barrier dysfunction that characterize the alcoholic lung.
INTRODUCTION
Chronic alcohol abuse, in addition to its well-known toxicities in the liver, brain, and other organs, is now recognized as a co-morbid variable that independently increases the incidence and severity of acute lung injury. Specifically, alcoholics are 2-4 times more likely to develop the Acute Respiratory Distress Syndrome (ARDS) in response to sepsis, trauma, or other acute inflammatory insults (25;27), and when they develop ARDS they have a higher incidence of extra-pulmonary organ failure (27) . ARDS is a common and devastating disease process estimated to afflict approximately 75,000-150,000 individuals per year in the United States alone (19;37). In the two epidemiological studies linking alcohol abuse and ARDS (25;27), ~50% of all individuals with ARDS were alcoholics, indicating that alcohol abuse causes tens of thousands of cases of ARDS per year. A cardinal feature of ARDS is alveolar epithelial cell dysfunction, including disruption of the alveolar epithelial barrier and flooding of the alveolar space with proteinaceous fluid rich in cytokines. Although incremental improvements in supportive care have improved survival in selected individuals (1) , the overall mortality from ARDS remains unacceptably high at 40-60% (37), and there are no effective pharmacological therapies to complement our current supportive care. The recently identified association between alcohol abuse and ARDS has prompted laboratory investigations that have generated new insights into the pathophysiology of acute lung injury, particularly in this highly vulnerable subgroup.
To study the fundamental mechanisms underlying the epidemiological association between alcohol abuse and ARDS, we developed a rat model of ethanol-mediated susceptibility to acute lung injury and determined that chronic ethanol ingestion produces multiple defects in alveolar epithelial function. More recently, we determined that transforming growth factor beta 1 (TGF 1 ) is induced by chronic ethanol ingestion and could mediate alveolar epithelial barrier dysfunction in the alcoholic lung during endotoxemia (4). Specifically, chronic ethanol ingestion increased gene and protein expression for TGF 1 in the rat lung (4). The majority of the TGF 1 protein in the alcoholic lung tissue is in the latent form but is released as activated TGF 1 into the alveolar airspace during endotoxemia, and the lavage fluid from these rats induces permeability in naive alveolar epithelial monolayer via TGF 1 -specific effects (4). Taken Lung tissue preparation for determination of TGF 1 . In selected experiments, rats were anesthetized with pentobarbital (60 mg/kg intraperitoneally), and a tracheostomy cannula was placed and secured with a 2-0 ligature. The chest cavity was opened, and 100 units of heparin were injected into the right ventricle and allowed to circulate for one minute. A perfusion catheter was placed in the pulmonary outflow tract and, after transection of the left atrium, the lungs were perfused blood-free with saline, excised free from other tissues, and stored at -70°C
for later analysis of TGF 1 protein levels by ELISA.
ELISA for determination of TGF 1 protein levels. For the tissue TGF 1 assays, frozen rat lung tissue (0.5 g) was combined with 2 ml of cold acid-ethanol (93% ethanol + 2% concentrated HCL), 85 µg/ml PMSF, and 5 µg/ml pepstatin A. This mixture was then homogenized 1-2 minutes with a polytron homogenizer. The samples were extracted overnight at 4°C by gentle rocking followed by centrifugation at 10,000 x g for 10 min. The pellets were then discarded, and the supernatants were dialyzed against 4 mM HCL using 3500 molecular weight cut-off LCMP-00141-2005 R1 dialysis tubing. Samples were again centrifuged at 13,000 x g for 10 min, and the supernatants were stored at -70°C until assayed. This preparation by necessity activates any latent TGF 1 in the tissue, because the commercial ELISA kit employed only detects the active form of TGF 1 ; therefore the measured levels represent total TGF 1 in the tissue (latent + active). Levels of TGF 1 in the lung lavage fluid and the prepared lung tissue were determined with a commercial ELISA kit (R&D Systems, Minneapolis, MN). Absorbance was read at 450 nm quantitated against a standard curve. The amount of TGF 1 in the lung lavage fluid and lung tissue was then expressed per mg of protein in each sample. For the lung lavage fluid TGF 1 assays, the lavage supernatants were not acidified prior to performing the ELISA, as we had previously determined that TGF 1 protein levels in the lavage fluid as determined by the commercial assay were not affected by acidification, indicating that all of the TGF 1 protein released into the alveolar space was in the free or active form (4).
Determination of lung liquid clearance in vivo.
As published previously (29), following induction of anesthesia a tracheostomy cannula was placed, a saline challenge (2cc) was given intratracheally, and the rats were mechanically ventilated with a Harvard rodent ventilator (tidal volume of 7 cc/kg at a rate of 60/min) for 30 min. The lungs were then removed en bloc and the right lung was isolated and its bronchus tied with a suture; the bronchus was then cut distal to the suture and the right lung weight was determined at baseline (wet weight) and then after desiccation overnight at 70°C (dry weight). The ratio of the wet weight to the dry weight was Eagle's Medium containing 10% serum, and 3 x 10 6 cells (3 ml) were plated on a 35 mm diameter permeable micro porous membrane (Transwell, Corning; 1 µm pore) and cultured for a total of 8 days at 37°C in 90% air/10% CO 2 .
Determination of alveolar epithelial barrier function in vitro.
The barrier function of the cell monolayers after 8 days in culture was determined as published previously (4) by adding 3 Hinulin and 14 C-sucrose (100,000 dpm) to the media covering the basolateral surfaces of the cultured cells. At multiple time intervals (15, 30, 60, or 120 min), the media covering the apical surfaces of the monolayers were removed and the radioactivity determined. Leak was defined as
the fraction of the initial radioactivity placed on the basolateral surface that appeared on the apical surface of the monolayer after 120 min (2 hrs).
Statistical Analysis.
Values shown represent the mean ± the standard error of the mean.
Values were compared by analysis of variance and corrected by Student-Newman-Keuls test for differences between groups. A p value of <0.05 was considered significant.
Effects of the ACE inhibitor, lisinopril, on ethanol-induced glutathione depletion within the alveolar microenvironment. We have shown that chronic ethanol ingestion induces oxidative stress within the alveolar compartment in rats and in humans, as reflected by decreased levels of the antioxidant, glutathione (GSH), in lung lavage fluid (17;26). To evaluate the potential role of the renin-angiotensin system in mediating this oxidative stress, we determined the levels of GSH in the alveolar epithelial lining fluid of control-fed rats, ethanol-fed rats, and ethanol-fed rats whose diets were supplemented with the ACE inhibitor, lisinopril. As shown in Figure 1 , chronic ethanol ingestion markedly decreased (P<0.05) levels of GSH in the lung lavage fluid compared to control-fed rats, and to a relative degree comparable to our findings in previous studies in this rat model (17) and in otherwise healthy alcoholic human subjects (26). In contrast, ethanol-fed rats that also received lisinopril in their diets had increased (P<0.05) levels of GSH in the lung lavage fluid when compared to untreated, ethanol-fed rats (Figure 1 ).
Although the levels of GSH were still slightly decreased (P<0.05) in lisinopril-treated, ethanolfed rats when compared to control-fed rats (Figure 1 ), approximately 80% of the ethanol-induced GSH depletion was prevented by lisinopril treatment.
Effects of angiotensin II inhibition or glutathione supplementation on lung tissue
expression of TGF 1 protein in ethanol-fed rats. Previously we determined that chronic ethanol ingestion approximately doubles the expression of TGF 1 protein in the lung (4).
However, the mechanism(s) by which ethanol induces TGF 1 expression was not addressed in that study. We hypothesized that TGF 1 expression was a consequence of angiotensin II-
induced oxidative stress in the alcoholic lung. Therefore, in these experiments we tested the effects of angiotensin II inhibitors and independently, glutathione supplementation, on TGF 1 expression in the lungs of ethanol-fed rats. As shown in Figure 2 , TGF 1 protein levels were increased (P<0.05) in the lungs of ethanol-fed rats as we have shown previously (4). In contrast, concomitant dietary treatment with the ACE inhibitor, lisinopril, or the angiotensin II receptor blocker, losartan, decreased TGF 1 protein levels in the lungs of ethanol-fed rats such that they
were not different (P>0.05) than levels in control-fed rat lungs (Figure 2 ). In parallel, glutathione supplementation with procysteine in ethanol-fed rats also decreased lung TGF 1 expression, as reflected by TGF 1 protein levels that were also not different (P>0.05) than those in control-fed rats (Figure 2 ). Taken together, the results shown in Figures 1 and 2 suggest that the renin-angiotensin system mediates lung oxidative stress during chronic ethanol ingestion, which in turn induces TGF 1 expression (see Discussion). For these experiments, rats were made endotoxemic but were not subjected to a saline challenge.
Effects of angiotensin II inhibition
As shown in Figure 6 , panel A, ethanol-fed rats released more than three times as much TGF 1 protein into the alveolar space during endotoxemia as control-fed rats (P<0.05). In contrast, rats fed the ethanol diet supplemented with lisinopril released the same (P>0.05) amount of TGF 1 protein into the alveolar space during endotoxemia as control-fed rats ( Figure 6 , panel A). As TGF 1 protein levels in the lavage fluids were corrected for total protein levels, we needed to ensure that the observed differences shown in panel A were relatively specific for TGF 1 and not simply a reflection of total protein accumulation in the airspace. Therefore, we also determined total protein concentrations in the lung lavage fluids of these endotoxemic rats. Lung lavage fluid recovery was not significantly different among the treatment groups (not shown), so protein
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concentrations were expressed per volume of lavage fluid. As shown in Figure 6 , panel B, total protein levels in the lavage fluids of endotoxemic, ethanol-fed rats were increased (P<0.05) compared to endotoxemic, control-fed rats. However, this increase in total protein was modest (~30%) and therefore could not account for the >300% increase in TGF 1 protein levels shown in panel A. In parallel with its effects on TGF 1 protein, lisinopril treatment decreased (P<0.05) total protein levels in the alveolar space in endotoxemic, ethanol-fed rats ( Figure 6, panel B) .
Overall, the results in Figure 6 are consistent with the results in Figure 2 , and suggest that angiotensin II not only induces the expression of TGF 1 protein in the alcoholic lung, it ultimately leads to changes in the lung that promote the release of TGF 1 protein into the alveolar airspace during an acute inflammatory stress such as endotoxemia.

DISCUSSION (paragraphs have been re-ordered in addition to text changes)
Our previous studies implicated glutathione depletion and increased TGF 1 expression in ethanol-induced alveolar epithelial dysfunction, and this current study unifies these pathophysiological pathways by revealing a common mechanism by which ethanol ingestion produces oxidative stress and induces TGF 1 expression within the lung. Specifically, we determined that dietary treatment with the angiotensin converting enzyme (ACE) inhibitor, lisinopril, which blocks ACE-dependent formation of angiotensin II, almost completely preserved glutathione levels within the alveolar space of ethanol-fed rats and prevented excess were measured with radiolabeled albumin (16). We cannot exclude the possibility that ethanol ingestion also perturbed lung lymphatic drainage and/or cardiovascular function in response to the intratracheal saline challenge, and that angiotensin II inhibition somehow reversed such defects. To our knowledge these potential mechanisms have not been examined in comparable models. However, the evidence from this study and our previous work strongly argues that ethanol-mediated susceptibility to acute edematous injury involves alveolar epithelial dysfunction.
Alcohol abuse increases the risk of developing the acute respiratory distress syndrome (ARDS) more than 3-fold during septic shock (27). This epidemiological association, which was first identified less than a decade ago (25), established alcohol abuse as the first co-morbid factor identified (and to date, the only factor) that independently increases the risk of ARDS. To study the mechanisms underlying this association, we developed a rat model of ethanol-induced susceptibility to acute lung injury (17;33) and determined that within 4-6 weeks of chronic ethanol ingestion, the lung shows signs of significant oxidative stress as reflected by profound appears to be the major cause of the alveolar epithelial oxidative stress and TGF 1 -mediated barrier disruption that characterize the alcoholic lung. These observations provide a previously unrecognized mechanism by which chronic ethanol ingestion renders the lung susceptible to acute edematous injury. The potential impact of these findings on our understanding of the pathophysiology of acute lung injury in the setting of alcohol abuse is enormous.
Pharmacological blockade of the actions of angiotensin II in other conditions, such as congestive heart failure and glomerular diseases, has dramatically improved survival in many individuals.
Clearly, additional studies are necessary before we can place alcohol-mediated susceptibility to acute lung injury on the list of serious human diseases for which inhibition of the reninangiotensin system is a therapeutic target. 
